After climbing steadily for seven years, the Parkinson disease death rate among older Americans has finally turned downward. New data from the National Center for Health Statistics shows that in 2024, the age-adjusted death rate for adults aged 65 and older stood at 72.0 deaths per 100,000—a meaningful decline from the peak of 76.3 recorded in 2021, and a signal that efforts to better manage this progressive neurological condition may be gaining traction.
The shift matters because Parkinson disease, which affects movement, balance, and cognitive function, has been claiming more lives over the past decade. Between 2014 and 2021, death rates climbed from 57.2 to 76.3 per 100,000—a troubling upward arc that researchers have been tracking closely. The reversal that began after 2021 offers a glimmer of hope for patients and families dealing with one of the most challenging neurodegenerative disorders.
Ellen A. Kramarow, Ph.D., and colleagues from the National Center for Health Statistics in Hyattsville, Maryland, analyzed data from the National Vital Statistics System to map these mortality trends. Their June 4 data brief reveals patterns that medical teams are now working to understand. Across all age groups—65 to 74, 75 to 84, and 85 and older—men consistently showed higher death rates from Parkinson disease than women in 2024. This disparity holds at every life stage, suggesting that gender may influence either disease severity, access to care, or underlying biological vulnerability.
Geography also plays a role. Death rates vary significantly by state, ranging from a low of 47.7 per 100,000 in New York to a high of 102.1 in Utah—more than double the rate. This wide variation suggests that some regions may have better access to specialized neurologists, more advanced treatment options, or different patterns in how Parkinson disease is diagnosed and recorded on death certificates. Race and ethnicity data show that White non-Hispanic adults had the highest death rates compared with other groups.
What makes the 2024 decline particularly significant is its consistency. As the researchers note, "Overall and for both men and women, death rates increased from 2014 through 2021 and were lower in 2024 than in 2021." This improvement spans across demographic groups, not concentrated in any single population. It suggests that advances may be working broadly—whether through better medications like newer dopamine agonists, improved deep brain stimulation techniques, or simply earlier diagnosis that allows for earlier intervention.
Parkinson disease remains a serious diagnosis, and a death rate of 72 per 100,000 among older adults reflects the profound impact this condition has on families and health systems. Yet the downward trajectory offers reason for cautious optimism. Researchers and clinicians are continuing to study what factors contributed to the decline after 2021, hoping to build on these gains. As the aging population grows, understanding mortality trends becomes ever more important—not just for measuring progress, but for identifying where resources and innovation can make the greatest difference in the years ahead.